Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$95.35
-0.7%
$76.26
$52.50
$96.56
$2.07B0.63715,150 shs414,021 shs
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$17.85
+6.5%
$14.93
$8.04
$25.88
$484.72M2.39738,803 shs511,439 shs
Harrow, Inc. stock logo
HROW
Harrow
$36.99
+2.2%
$35.29
$20.85
$59.23
$1.37B0.33659,179 shs354,912 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$14.39
+6.4%
$14.08
$6.00
$22.00
$1.84B2.26180,119 shs379,111 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-0.68%+1.98%+38.01%+53.89%+51.49%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
+6.50%+4.94%+46.19%+39.56%-6.35%
Harrow, Inc. stock logo
HROW
Harrow
+2.18%-5.15%+12.02%+25.01%-5.85%
Mesoblast Limited stock logo
MESO
Mesoblast
+6.43%+4.05%-8.11%+22.05%+119.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$95.35
-0.7%
$76.26
$52.50
$96.56
$2.07B0.63715,150 shs414,021 shs
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$17.85
+6.5%
$14.93
$8.04
$25.88
$484.72M2.39738,803 shs511,439 shs
Harrow, Inc. stock logo
HROW
Harrow
$36.99
+2.2%
$35.29
$20.85
$59.23
$1.37B0.33659,179 shs354,912 shs
Mesoblast Limited stock logo
MESO
Mesoblast
$14.39
+6.4%
$14.08
$6.00
$22.00
$1.84B2.26180,119 shs379,111 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-0.68%+1.98%+38.01%+53.89%+51.49%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
+6.50%+4.94%+46.19%+39.56%-6.35%
Harrow, Inc. stock logo
HROW
Harrow
+2.18%-5.15%+12.02%+25.01%-5.85%
Mesoblast Limited stock logo
MESO
Mesoblast
+6.43%+4.05%-8.11%+22.05%+119.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
3.10
Buy$84.75-11.12% Downside
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.00
Buy$50.57183.31% Upside
Harrow, Inc. stock logo
HROW
Harrow
3.13
Buy$64.6774.82% Upside
Mesoblast Limited stock logo
MESO
Mesoblast
3.20
Buy$18.0025.09% Upside

Current Analyst Ratings Breakdown

Latest ARCT, MESO, ANIP, and HROW Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$60.00
8/22/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$63.00 ➝ $54.00
8/21/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
8/14/2025
Harrow, Inc. stock logo
HROW
Harrow
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
8/14/2025
Harrow, Inc. stock logo
HROW
Harrow
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$62.00 ➝ $63.00
8/13/2025
Harrow, Inc. stock logo
HROW
Harrow
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$60.00 ➝ $64.00
8/12/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$47.00 ➝ $49.00
8/12/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$45.00 ➝ $42.00
8/11/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$65.00 ➝ $77.00
8/8/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$84.00 ➝ $93.00
8/8/2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$94.00
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$614.38M3.37$7.60 per share12.55$19.11 per share4.99
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$152.31M3.18N/AN/A$8.90 per share2.01
Harrow, Inc. stock logo
HROW
Harrow
$199.61M6.86$0.14 per share270.51$1.95 per share18.97
Mesoblast Limited stock logo
MESO
Mesoblast
$17.20M107.09N/AN/A$4.21 per share3.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-$18.52M-$0.77N/A22.65N/A-1.37%25.03%8.00%11/14/2025 (Estimated)
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)
Harrow, Inc. stock logo
HROW
Harrow
-$17.48M-$0.25N/A92.48N/A-4.49%-2.18%-0.35%11/12/2025 (Estimated)
Mesoblast Limited stock logo
MESO
Mesoblast
-$87.96MN/A0.00N/AN/AN/AN/AN/AN/A

Latest ARCT, MESO, ANIP, and HROW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million
8/11/2025Q2 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.01$0.24+$0.23$0.13$64.23 million$63.74 million
8/8/2025Q2 2025
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$1.42$1.80+$0.38$0.36$187.18 million$211.37 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
Mesoblast Limited stock logo
MESO
Mesoblast
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
1.39
2.54
1.96
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/A
5.90
5.90
Harrow, Inc. stock logo
HROW
Harrow
0.78
0.62
0.58
Mesoblast Limited stock logo
MESO
Mesoblast
0.11
1.99
0.63

Institutional Ownership

CompanyInstitutional Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
94.54%
Harrow, Inc. stock logo
HROW
Harrow
72.76%
Mesoblast Limited stock logo
MESO
Mesoblast
1.43%

Insider Ownership

CompanyInsider Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
11.10%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
16.60%
Harrow, Inc. stock logo
HROW
Harrow
15.16%
Mesoblast Limited stock logo
MESO
Mesoblast
18.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
60021.70 million19.29 millionOptionable
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
18027.16 million22.65 millionOptionable
Harrow, Inc. stock logo
HROW
Harrow
18037.00 million31.39 millionOptionable
Mesoblast Limited stock logo
MESO
Mesoblast
80128.00 million103.93 millionOptionable

Recent News About These Companies

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
Mesoblast (NASDAQ:MESO) Shares Gap Down - What's Next?
Mesoblast Full Year 2025 Earnings: Misses Expectations
Examining the Future: Mesoblast's Earnings Outlook
Examining the Future: Mesoblast's Earnings Outlook
Mesoblast (NASDAQ:MESO) Shares Gap Up - Time to Buy?

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANI Pharmaceuticals stock logo

ANI Pharmaceuticals NASDAQ:ANIP

$95.35 -0.65 (-0.68%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$95.30 -0.05 (-0.05%)
As of 09/5/2025 05:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Arcturus Therapeutics stock logo

Arcturus Therapeutics NASDAQ:ARCT

$17.85 +1.09 (+6.50%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$17.96 +0.11 (+0.64%)
As of 09/5/2025 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Harrow stock logo

Harrow NASDAQ:HROW

$36.99 +0.79 (+2.18%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$37.33 +0.34 (+0.91%)
As of 09/5/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Mesoblast stock logo

Mesoblast NASDAQ:MESO

$14.39 +0.87 (+6.43%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$14.07 -0.32 (-2.22%)
As of 09/5/2025 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.